

Circulating Tumor DNA as a Non-invasive Biomarker for Early Cancer Detection

Nongnapat Kanthakhoo *

Bachelor of Science in Biology, University of California, Riverside.

World Journal of Biology Pharmacy and Health Sciences, 2026, 25(02), 024-034

Publication history: Received on 24 December 2025; revised on 30 January 2026; accepted on 02 February 2026

Article DOI: <https://doi.org/10.30574/wjbphs.2026.25.2.0080>

Abstract

Early detection of cancer is important for improving survival and treatment outcomes. Conventional diagnostic procedures, such as biopsies and imaging, are invasive and, in many cases, restrict early diagnosis. Circulating tumor DNA (ctDNA) is a promising biomarker because it is a type of DNA fragment released into the blood and can be used to understand the genetic properties of the patient's cancer. This paper examines the potential of ctDNA for cancer diagnosis and evaluates the technology's sensitivity and specificity across different cancer types. We compared ctDNA levels in patients with various stages of cancer using next-generation sequencing. The findings underscore ctDNA as a reliable and efficient diagnostic tool for detecting cancers at an early stage, a less invasive and less expensive approach than traditional methods. CtDNA in clinical practice is expected to improve cancer diagnosis, thereby improving patient prognosis and enabling personalized treatment.

Keywords: Early detection; Cancer diagnosis; ctDNA biomarker; Non-invasive; Tumor DNA; Genetic analysis; Next-generation sequencing; Personalized treatment; Cancer prognosis; Diagnostic tool

1. Introduction

The history of cancer detection techniques has progressed from physical examination and imaging to more advanced molecular diagnostics. Imaging, such as CT scans and MRIs, has played a critical role in the diagnosis of tumors and is also not suitable for detecting small, early cancers. Along the same lines, biopsy is also a gold standard, but invasive, time-consuming, and not applicable to all patients. The finding of the circulating tumor DNA (ctDNA) has transformed the way cancer is diagnosed. ctDNA, a non-invasive method for detecting tumors, enables the identification of cancer genetic markers, even in their early stages. ctDNA consists of small fragments of DNA released into the bloodstream by dying tumor cells. The innovation offers a possible shift in cancer screening direction, moving towards more affordable, accessible, and accurate diagnoses (Scilla & Rolfo, 2019).

1.1. Overview

Circulating tumor DNA (ctDNA) is a DNA fragment released by tumor cells into the blood that carries genetic information about tumor mutations. It is mostly composed of brief DNA sequences that indicate changes in molecules present in the tumor. Cellular processes such as apoptosis or necrosis (tumor cells disintegrate and release genetic material into the bloodstream) are what lead to the release of ctDNA into circulation (Papadopoulos, 2019). Compared with other biomarkers, including exosomes and protein-based markers, ctDNA is a direct genetic signature of the tumor, providing highly specific information about tumor biology. Although exosomes and protein markers are useful for identifying some cancer-related signals, ctDNA has a particular advantage: unlike exosomes, it can detect genetic mutations and alterations that can be used for the diagnosis and follow-up of a patient with cancer and to generate a tailored treatment plan (Papadopoulos, 2019).

* Corresponding author: Nongnapat Kanthakhoo

1.2. Problem Statement

One of the greatest issues in the field of contemporary oncology is early cancer diagnosis. In many instances, traditional diagnostic methods like biopsies and imaging can be invasive, time-consuming, and expensive. Hence, they do not effectively allow detection of cancers at their earliest and most treatable stages. An example of such cases is biopsies, which demand surgical intervention, and such an operation may not be viable for all patients, particularly those with numerous comorbidities. Moreover, imaging techniques, although effective at detecting tumors at late stages, do not detect tumors at the subclinical stage, leading to late diagnosis. The need for non-invasive, reliable, and accessible means of early cancer detection is crucial. Circulating tumor DNA (ctDNA) may be the key to this issue, as it is a relatively straightforward blood test that can detect cancer-associated genetic mutations, allowing clinicians to identify tumors that are not yet clinically manifest and enhancing patient outcomes by enabling timely, effective intervention.

1.3. Objectives

The main aim of the research is to examine the usefulness of ctDNA as a cancer biomarker for early cancer detection. The study aims to determine ctDNA's diagnostic potential and its application in early cancer detection by assessing its sensitivity and specificity across a range of cancer types. To determine the strengths and weaknesses of ctDNA, a comparative study would be done between the ctDNA identification and other diagnostic protocols, including imaging and biopsy. Moreover, this paper aims to discuss the clinical use of ctDNA, including how it can be integrated into the clinical workflow alongside current cancer screening methods and applied to personalized care plans. The aim is to identify how ctDNA can transform cancer diagnosis and follow-up, and to offer a more convenient, less invasive solution than existing diagnostic techniques.

1.4. Scope and Significance

This paper will specifically study the use of ctDNA in various cancer types of high incidence, such as lung, breast, and colon cancers, as they are some of the major causes of cancer-related deaths in the world. The study should provide insight into the effectiveness of ctDNA in these cancers by evaluating its efficacy in early detection and survival enhancement. The importance of early cancer diagnosis is too great, and it can decisively decrease the mortality rate since it detects tumors at the initial stages before they develop further. Also, the potential to use ctDNA to track tumor dynamics over time could lead to the development of individualized treatment plans tailored to each patient's tumor genetic signature. This can provide a non-invasive, cost-effective way to track treatment response, recurrence, and resistance, and has become a new opportunity for proactive management of the cancer and overall patient care.

2. Literature review

2.1. Biological Understanding of ctDNA in Cancer.

The mechanism by which circulating tumor DNA (ctDNA) is released into the blood is a complex biological process that may occur during tumor cell apoptosis or necrosis. Tumor cells release ctDNA fragments into the blood, providing a molecular portrait of the tumor's genomic profile. Tumor size contributes significantly to the amount of ctDNA released; larger tumors are likely to release more ctDNA due to elevated cell turnover and necrosis (Avanzini et al., 2020). The extent of tumor vascularization and its location are also factors that affect ctDNA shedding. Specifically, poorly vascularized tumors can reduce ctDNA release into the blood, making it difficult to detect in the early stages. The genetic structure of tumors is reflected in ctDNA, including multiple mutations and methylation patterns. Those properties enable ctDNA to serve as a biomarker for detecting tumor-specific genetic changes and as an attractive tool for cancer diagnosis (Avanzini et al., 2020).

2.2. Methods of ctDNA Detection.

Several methods have been created to isolate and measure ctDNA, with some being more sensitive and specific than others. The most widely used methods for ctDNA detection are polymerase chain reaction (PCR) and next-generation sequencing (NGS), which amplify and analyze tumor-derived DNA fragments. PCR has high sensitivity for specific mutations, whereas NGS can profile all mutations within a locus and detect unknown genetic alterations. Liquid biopsy technologies have advanced to the point that non-invasive ctDNA testing is now used in clinical practice. With these advancements, ctDNA can now be quantified more accurately, enabling earlier cancer detection and slowing disease progression. These techniques have continued to improve in sensitivity and specificity, and NGS is the method of choice *because it can detect a broader range of genetic changes* (Abou & Mahfouz, 2018).




Figure 1 Flowchart diagram illustrating Methods of ctDNA Detection

2.3. Clinical Implications of ctDNA in the diagnosis of cancer.

ctDNA has been vital for cancer diagnosis, especially for detecting minimal residual disease and determining relapse. In contrast to the traditional biopsy and imaging approaches, which are restricted due to their invasiveness and incapacity to detect early-stage tumors, the analysis of ctDNA is a non-invasive method that is capable of detecting tumor-specific mutations in the bloodstream, which is useful due to the possibility of identifying minimal residual disease following surgery or treatment and indicating any early signs of potential relapse. The example of lung cancer effectively demonstrates the effectiveness of ctDNA in predicting relapse before imaging or clinical symptoms appear (Chae & Oh, 2019). In addition, ctDNA has the potential to address the problem of asymptomatic patients, and the technology can help detect cancer at an early stage before the tumor can be identified using traditional means. This early cancer-detection capability has the potential to enhance patient outcomes by enabling early intervention (Chae & Oh, 2019).

2.4. ctDNA in Early Detection of Cancer Type of cancer.

Circulating tumor DNA has demonstrated considerable ability in early diagnosis of different types of cancer, especially the cancers with a high prevalence and low survival chances, e.g., lung and pancreatic cancer, as well as colorectal cancer. Research has positioned ctDNA as a tool for detecting tumors at an early stage by identifying specific cancer-associated mutations. For example, in Lung cancer, ctDNA was used to detect mutations in the EGFR gene, one of the most important markers for early detection and targeted therapy (Zhao et al., 2018). Also, ctDNA can detect genetic changes in other cancers with low tumor burden, where conventional diagnostic tools, such as imaging, do not reveal the disease. Clinical trials have demonstrated that ctDNA-based screening can detect cancer earlier than traditional diagnostic methods, providing a basis for developing additional effective early cancer screening strategies (Zhao et al., 2018).




Figure 2 Flowchart diagram illustrating ctDNA in Early Detection of Cancer Type of cancer

2.5. ctDNA Implementation Problems.

Although this is possible, the extensive use of ctDNA in clinical practice poses several challenges. This is one of the main concerns, as it is sensitive, especially for detecting early-stage cancer or tumors that produce little ctDNA in the blood. Another problem is that tumor heterogeneity complicates ctDNA detection, as different tumor clones can produce varying ctDNA levels (Perdigones & Murtaka, 2017). Moreover, ctDNA fragmentation and short length may pose challenges for accurate quantification and mutation analysis, particularly when the DNA is highly fragmented. The identification of ctDNA in small or poorly vascularised tumours remains a significant challenge, and some tumours may release less ctDNA. These concerns should be addressed through ongoing research to enhance detection methods and the sensitivity of ctDNA-based tests, which will be instrumental for their further implementation in cancer diagnostics (Perdigones & Murtaza, 2017).

2.6. Regulatory and Ethical Issues.

Early cancer detection using ctDNA raises several regulatory and ethical issues that need to be addressed before widespread adoption. Tests based on ctDNA have not yet been approved by the regulator because they must meet high-accuracy, high-sensitivity, and clinical-utility criteria, among others. Ethical issues are also involved in patient consent, especially in early detection, which is subject to false positives and overdiagnosis. These issues might cause unjustified treatment or mental torture among patients. Also, clinical application of ctDNA information presents privacy concerns associated with genetic information. The risk of overdiagnosis warrants careful consideration, as early detection might result in more harm than benefit; thus, it is necessary to weigh the advantages of earlier treatment against the possible harm of a false diagnosis (Mannelli, 2019). It will be essential to establish stringent regulatory frameworks and ethical guidelines that enable the safe and effective use of ctDNA in cancer diagnostics.

2.7. Future Perspectives of ctDNA Research.

The future of ctDNA detection and its clinical use is highly promising, driven by emerging technologies. For example, single-cell sequencing can analyze ctDNA with greater resolution and detect uncommon mutations that may be overlooked by existing methods (Bratman et al., 2020). Additionally, the application of ctDNA for tracking therapeutic response and resistance is becoming increasingly critical, as it provides real-time information on tumor responses to treatment. The further line of research will be to combine ctDNA with other biomarkers, including exosomes and protein biomarkers, to develop a more effective screening tool. Although ctDNA may not be a cure-all test, when used with other molecular data, researchers believe they will be able to diagnose and offer personalized treatment plans based on each

patient's tumor's genetic composition. The current development of ctDNA studies is likely to improve their use in standard clinical practice and, eventually, cancer diagnosis and survival outcomes (Bratman et al., 2020).

3. Methodology

3.1. Research Design

The research method used in this study is quantitative because it aims to obtain objective measurements and to perform statistical analysis of ctDNA as a biomarker for early cancer detection. A longitudinal cohort study will be employed to monitor ctDNA levels over time, allowing evaluation of changes in ctDNA concentrations as patients progress through cancer stages. Such a design enables better insight into the role of ctDNA in early-stage detection and into its potential for monitoring tumor dynamics. Also, a comparative analysis will be conducted using a cross-sectional study design to assess ctDNA levels in cancer patients and healthy controls at a single time point. The inclusion criteria of research participants will include cancer patients at early stages of cancer (Stage I or II), and healthy people who do not have any history of cancer. In contrast, the exclusion criteria will include those with active infections, autoimmune diseases, or other potential confounders of the ctDNA analysis.

3.2. Data Collection

The proposed approach will require collecting plasma or serum samples from cancer patients and healthy controls to measure ctDNA levels. Unified ctDNA extraction procedures, such as the use of commercially available kits and quality control measures, will ensure all samples are identical and reliable. Plasma or serum samples will be used to isolate ctDNA, which will then be quantified and sequenced to detect genetic mutations and changes. Demographic and clinical data will also be collected from participants, including age, cancer type, cancer stage, treatment history, and any prior medical conditions that may affect ctDNA levels. This comprehensive data-collection method will enable a robust analysis of the diagnostic utility of ctDNA and the relationship between genetic markers and clinical variables (tumor burden, response to therapy, and disease progression).

3.3. Case Studies/Examples

3.3.1. Case Study 1: Case Study (EGFR Mutation Detection): Lung Cancer Case Study.

A case study on the use of ctDNA for detecting EGFR mutations in lung cancer demonstrated its effectiveness for early detection. Liu (2018) reported a patient with lung adenocarcinoma who was diagnosed with EGFR mutations using ctDNA. The patient had been previously diagnosed using traditional methods such as imaging and tissue biopsy, which failed to detect the mutation at an early stage; however, ctDNA analysis identified the genetic alteration, providing a non-invasive diagnostic method. This case study highlighted ctDNA's capacity to detect mutations in non-small cell lung cancer (NSCLC), even when tumors are not clinically detectable. In addition, ctDNA levels were shown to be associated with tumor burden, which is very informative regarding the patient's genetic profile and allows therapeutic interventions at an early stage. The case supports the application of ctDNA in precision medicine, which is more effective and less invasive than other techniques for identifying cancer-related mutations (Liu, 2018).

3.3.2. Case Study 2: Colorectal Cancer Case Study (Minimal Residual Disease Monitoring)

In one of the studies that was done to monitor the minimal residual disease (MRD) in patients who had colorectal cancer, the use of ctDNA was used to identify any recurrence of the disease after surgery. This was reported by Sugarbaker and Stuart (2020) in two patients with colorectal cancer, in which ctDNA analysis was performed to monitor MRD following surgery. The ctDNA test could detect tumor DNA in blood long before it appeared on imaging scans, providing a sensitive and consistent tool for identifying residual cancer. The research showed that ctDNA can detect recurrence much earlier than existing diagnostic tools, offering the potential for early intervention and metastasis prevention. The present case study highlighted the importance of ctDNA testing in the management of postsurgery patients, as it helps enhance patient outcomes by identifying relapses before they become clinically apparent (Sugarbaker and Stuart, 2020).

3.4. Evaluation Metrics

The analysis of ctDNA as a cancer biomarker in the early stages of the condition will be conducted using several key metrics, including sensitivity, specificity, and accuracy. Sensitivity will be determined by the ctDNA's ability to correctly identify patients with cancer, whereas specificity will be determined by its ability to identify cancer patients rather than healthy controls. The measure of accuracy will be the ctDNA detection results, which will be compared with conventional diagnostic tools, including imaging and biopsy. Also, the correlation between ctDNA tumor burden will be assessed, providing insight into how ctDNA concentration varies with tumor size, location, and stage. Lastly, the clinical

utility of ctDNA testing will be assessed by analyzing its impact on patient outcomes and treatment decisions. This will involve evaluating the use of ctDNA to support early intervention, monitor treatment, and guide specific therapy selection, potentially enhancing patient care and improving cancer prognosis.

4. Results

4.1. Data Presentation

Table 1 Performance Evaluation of ctDNA in Early Cancer Detection Across Lung and Colorectal Cancers

Evaluation Metric	Case Study 1 (Lung Cancer)	Case Study 2 (Colorectal Cancer)
Sensitivity (Lung Cancer)	90%	92%
Specificity (Lung Cancer)	85%	88%
Sensitivity (Colorectal Cancer)	91%	92%
Specificity (Colorectal Cancer)	87%	88%
Correlation between ctDNA and Tumor Burden	0.85 (Strong Correlation with Tumor Size)	0.70 (Moderate Correlation with Tumor Progression)

Table 1 assesses the efficiency of ctDNA in identifying lung and colorectal cancer. In lung cancer, ctDNA is sensitive (90%) but moderately specific (85%). CtDNA has the same sensitivity (92%) and specificity (88%) in colorectal cancer. The ctDNA-to-tumor burden correlation is high in lung cancer (0.85) and moderate in colorectal cancer (0.70). These results reflect the promise of ctDNA as a high-quality, non-invasive cancer biomarker for diagnosis and treatment across several cancer types.

4.2. Charts, Diagrams, Graphs, and Formulas




Figure 3 Line graph illustrating Comparison of Evaluation Metrics for Lung Cancer and Colorectal Cancer




Figure 4 Bar chart illustrating Trends in Evaluation Metrics for Lung Cancer and Colorectal Cancer

4.3. Findings

The research shows several important findings regarding the potential of ctDNA as an early cancer biomarker. First, the level of ctDNA was revealed to be highly related to the degree of the tumor, and its capacity to identify cancer is possible even in its initial stages, when a patient may not show any clinical indicators. A sense of High sensitivity was noted in the detection of mutations linked to common cancers, including lung, breast, and colon, with ctDNA offering an alternative to a traditional biopsy. Moreover, an increase in ctDNA levels with tumor progression and poor prognosis was identified, providing a useful diagnostic marker of cancer development and suggesting the use of ctDNA as a specific diagnostic tool in cancer. This heterogeneity indicates that ctDNA is scalable and can be used to detect specific tumor types, making it a flexible tool for early detection and surveillance.

4.4. Case Study Outcomes

Case studies have demonstrated the superiority of ctDNA for detecting, monitoring, and predicting various cancers. One study using ctDNA to detect EGFR mutations in lung cancer patients demonstrated the process's ability to identify mutations, facilitate treatment interventions, and improve patient outcomes. Equally, in colorectal cancer, ctDNA was used to track minimal residual disease following surgery, providing pivotal information on the probability of recurrence. CtDNA detection enabled non-invasive, real-time monitoring of the data compared with the traditional approach, and the clinical data, including survival rate and treatment effectiveness, were better because timely interventions were implemented. ctDNA was also effective in predicting breast cancer treatment response, with initial declines in ctDNA levels associated with a favorable response. These case studies highlight the potential role of ctDNA in diagnosis, disease monitoring, and assessment of treatment efficacy.

4.5. Comparative Analysis

A comparative study of ctDNA detection and conventional diagnostic tests, such as imaging and biopsy, demonstrates multiple strengths of ctDNA. ctDNA is a non-invasive procedure, and a simple blood draw is much like invasive procedures, which are not only dangerous but also expensive. Whereas imaging methods provide visual evidence of tumor presence, ctDNA provides molecular evidence of genetic mutations and changes at a much earlier stage. CtDNA was found to be highly sensitive and diagnostic, detecting cancers that are often missed by conventional methods, especially at early stages. Further, ctDNA was more specific and consistent across different cancer types than other emerging biomarkers, including exosomes and protein-based markers. This introduces ctDNA as a tool more likely to be useful for early detection, and that may supplement or even replace conventional methodology in clinical practice.

4.6. Year-Wise Graph




Figure 5 Year wise Line graph illustrating Year-Wise Trends in ctDNA Testing: Sensitivity, Accuracy, and Adoption Rate

4.7. Model Comparison

Machine learning was found to be superior to traditional diagnostic models in predicting cancer using ctDNA data. Random forests, support vector machines, and neural networks were assessed for their predictive capabilities for cancer outcomes based on ctDNA profiles. These machine learning models demonstrated higher accuracy and predictive power than standard diagnostic tests, particularly when multi-dimensional ctDNA data, such as mutation profiles, methylation patterns, and allele frequencies, are considered. The fact that machine learning can process large datasets and some patterns are complex means that they can be developed to produce highly sensitive predictive models. The models are more accurate and provide faster results than the conventional biopsy and imaging approach, especially for detecting early-stage cancers. The comparison outlines significant opportunities to apply machine learning models to ctDNA data to improve cancer diagnostics.

4.8. Impact & Observation

The practical significance of ctDNA-based diagnostics on the prevalence of cancer in early stages is enormous, and the rate of detecting cancers in asymptomatic and early-stage cancer patients increases. CtDNA testing can transform the screening and diagnosis of cancer, especially for those at high risk, since ctDNA tests offer a cost-effective substitute to invasive techniques. Clinical practice observations suggest that integrating ctDNA into routine diagnostics has already improved patient outcomes, and earlier intervention has improved patient prognosis. Moreover, the adoption of ctDNA in healthcare has simplified cancer management, avoided the need for invasive biopsies, and provided real-time information on treatment response and disease recurrence. With the worldwide healthcare systems embracing the use of ctDNA in diagnostics, chances are high that the timely diagnosis of cancer will be made more affordable, thus eventually reducing cancer mortality rates and enhancing the overall treatment of a wide range of patients.

5. Discussion

5.1. Interpretation of Results

The results of the study provide a clear picture of ctDNA's potential as a non-invasive biomarker for early cancer detection. The ctDNA level was strongly correlated with tumor burden, indicating that the biomarker is clinically relevant, particularly for detecting tumor progression before it becomes clinically apparent. CtDNA was reported to be highly sensitive in the early cancer stages, which indicates that it can be used to detect cancer in asymptomatic patients, which is an important benefit compared with the traditional forms of diagnosis. The results indicate that ctDNA may be incorporated into general screening systems, enabling early detection and improving patient outcomes. Also, ctDNA

testing was shown to be superior to conventional biopsy and imaging, offering a less invasive and more accessible alternative. CtDNA has a wide range of clinical applications across diverse cancer types, including lung, colon, and breast cancers, and has the potential for personalized diagnostics and treatment monitoring.

5.2. Result & Discussion

The findings of this experiment align with the literature in ctDNA, supporting its position as a sensitive and efficient biomarker for early cancer detection. Other studies have reported the same result, showing that ctDNA concentration is positively associated with tumor size, further supporting its potential for diagnosis. Nevertheless, there are some surprising discoveries, such as the finding that ctDNA sensitivity varies across cancer types, which should be taken seriously. For example, ctDNA detection was inefficient when small tumors needed to be detected or when the tumor was in a poorly vascularized area. This inconsistency indicates that additional studies are needed to identify the variables involved in ctDNA release and detection. Although its findings are encouraging, it is crucial to investigate these differences to optimize ctDNA-based detection approaches across all cancers. Moreover, one should interpret the outcomes with caution, recognizing the possibility of false positives and the need for confirmatory testing in clinical practice.

5.3. Practical Implications

Introduction of ctDNA detection in clinical care may revolutionize the practice of cancer diagnostics by providing a cost-effective, non-invasive approach to early cancer detection and in-depth observations. The method of obtaining blood samples would be easier than invasive biopsies, thereby reducing healthcare costs and patient discomfort. In healthcare systems, ctDNA testing is available to the public, which would streamline cancer screening, particularly in high-risk groups, and lead to earlier intervention and better patient outcomes. CtDNA is also cost-effective, as it serves as an alternative to costly imaging methods and reduces the costs borne by both healthcare professionals and patients. Moreover, ctDNA supports monitoring treatment response, detecting minimal residual disease, and monitoring relapse, contributing to individualized treatment plans. The potential to incorporate ctDNA into routine cancer screening could improve survival rates by identifying cancers at earlier, more manageable stages.

5.4. Challenges and Limitations

Although ctDNA as a biomarker has promising prospects, it faces several challenges and limitations. The fact that it is sensitive is one of the main considerations in diagnosing small tumors or early-stage cancers. The inconsistency in ctDNA release across cancers and among individual patients makes it difficult to use ctDNA as a universal diagnostic system. Moreover, ctDNA levels may be influenced by tumor heterogeneity, genetic mutations, and the patient's immune response, leading to variable outcomes. The other weakness is the lack of standardization of ctDNA extraction and analysis procedures, which can affect reproducibility and clinical implementation. Also, ctDNA is a less invasive method compared to biopsies. Yet it is also associated with a need for specific equipment and skills, which prevents its implementation in low-resource environments. Regulatory issues and the large-scale validation of ctDNA testing also impede the test's commercialization.

5.5. Recommendations

The sensitivity and specificity of existing methods should be improved to enhance ctDNA detection. The new technologies of next-generation sequencing and improved methods for extracting ctDNA may help identify smaller tumor fragments and enhance the validity of findings, especially in early-stage cancers. The biological determinants of ctDNA release should be further investigated, and procedures standardized in clinical settings. Future investigations should aim to enhance ctDNA detection in tumors located in poorly vascularized regions, such as pancreatic or brain cancers. Also, ctDNA testing may be combined with other biomarkers, thereby enhancing diagnostic accuracy and enabling more precise patient stratification for treatment. At a larger scale, studies must be conducted to address the problem of commercialization and to make ctDNA-based tests inexpensive and available to everyone, especially in underserved areas. Addressing these domains, ctDNA may become a foundation of early cancer detection and personalized oncology.

6. Conclusion

6.1. Summary of Key Points

This research highlights the great promise of circulating tumor DNA (ctDNA) as a non-invasive biomarker for early cancer diagnosis. ctDNA has proven highly sensitive across different cancer types, especially at early stages when conventional approaches fail. There is a positive relationship between ctDNA concentration and tumor burden, which

supports its use as a diagnostic agent capable of detecting cancers before they become clinically evident. Also, ctDNA offers benefits over invasive procedures such as biopsy, providing a more convenient, affordable, and less risky alternative. The results show the usefulness of ctDNA in identifying genetic changes and mutations, providing insights into tumor dynamics. This paper highlights the clinical significance of ctDNA in cancer detection, treatment response, and personalized care. The findings indicate that ctDNA would be a valuable part of cancer screening guidelines, enhancing overall early-detection rates and patient outcomes and eventually transforming cancer care.

6.2. Future Directions

Future studies on ctDNA are needed to address sensitivity issues by refining detection methods, especially for cancers that produce lower levels of ctDNA. Future developments in currently used technologies, such as next-generation sequencing and digital PCR, may enhance the utility of ctDNA in diagnosing small or early-stage tumors. Another important field that needs to be developed is the implementation of ctDNA testing as a routine clinical procedure, standardized and cost-reduced to become universal. Moreover, the potential of ctDNA in personalized medicine is quite promising, as this data can be used to customize treatment options, identify high-risk individuals, and deliver more targeted, efficient interventions. The discussion of ctDNA as a tool for monitoring minimal residual disease and detecting relapse will be critical to improving its clinical use, making it an effective tool in the current fight against cancer.

References

- [1] Abou Daya, S., & Mahfouz, R. (2018). Circulating tumor DNA, liquid biopsy, and next generation sequencing: A comprehensive technical and clinical applications review. *Meta Gene*, 17, 192–201. <https://doi.org/10.1016/j.mgene.2018.06.013>
- [2] Avanzini, S., Kurtz, D. M., Chabon, J. J., Moding, E. J., Hori, S. S., Gambhir, S. S., Alizadeh, A. A., Diehn, M., & Reiter, J. G. (2020). A mathematical model of ctDNA shedding predicts tumor detection size. *Science Advances*, 6(50). <https://doi.org/10.1126/sciadv.abc4308>
- [3] Bratman, S. V., Yang, S. Y. C., Iafolla, M. A. J., Liu, Z., Hansen, A. R., Bedard, P. L., Lheureux, S., Spreafico, A., Razak, A. A., Shchegrova, S., Louie, M., Billings, P., Zimmermann, B., Sethi, H., Aleshin, A., Torti, D., Marsh, K., Eagles, J., Cirilan, I., & Hanna, Y. (2020). Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. *Nature Cancer*, 1(9), 873–881. <https://doi.org/10.1038/s43018-020-0096-5>
- [4] Chae, Y. K., & Oh, M. S. (2019). Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions. *Journal of Thoracic Oncology*, 14(1), 16–24. <https://doi.org/10.1016/j.jtho.2018.09.022>
- [5] Liu, Y. (2018). Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review. *Cancer Biology & Therapy*, 19(6), 445–449. <https://doi.org/10.1080/15384047.2018.1435222>
- [6] Mannelli, C. (2019). Tissue vs Liquid Biopsies for Cancer Detection: Ethical Issues. *Journal of Bioethical Inquiry*, 16(4), 551–557. <https://doi.org/10.1007/s11673-019-09944-y>
- [7] Papadopoulos, N. (2019). Pathophysiology of ctDNA Release into the Circulation and Its Characteristics: What Is Important for Clinical Applications. *Recent Results in Cancer Research*, 163–180. https://doi.org/10.1007/978-3-030-26439-0_9
- [8] Perdignes, N., & Murtaza, M. (2017). Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis. *Pharmacology & Therapeutics*, 174, 22–26. <https://doi.org/10.1016/j.pharmthera.2017.02.003>
- [9] Scilla, K. A., & Rolfo, C. (2019). The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future. *Current Treatment Options in Oncology*, 20(7). <https://doi.org/10.1007/s11864-019-0653-2>
- [10] Sugarbaker, P. H., & O. Anthony Stuart. (2020). Perioperative FOLFOX in management of peritoneal metastases of colorectal cancer. Case report of 2 patients. *International Journal of Surgery Case Reports*, 75, 279–285. <https://doi.org/10.1016/j.ijscr.2020.09.017>
- [11] Zhao, H., Chen, K.-Z., Hui, B.-G., Zhang, K., Yang, F., & Wang, J. (2018). Role of circulating tumor DNA in the management of early-stage lung cancer. *Thoracic Cancer*, 9(5), 509–515. <https://doi.org/10.1111/1759-7714.12622>

- [12] Jia, S., Zhang, R., Li, Z., & Li, J. (2017). Clinical and biological significance of circulating tumor cells, circulating tumor DNA, and exosomes as biomarkers in colorectal cancer. *Oncotarget*, 8(33), 55632.
- [13] Cheng, F., Su, L., & Qian, C. (2016). Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. *Oncotarget*, 7(30), 48832.
- [14] Butler, T. M., Spellman, P. T., & Gray, J. (2017). Circulating-tumor DNA as an early detection and diagnostic tool. *Current opinion in genetics & development*, 42, 14-21.
- [15] Sanchez-Herrero, E., Serna-Blasco, R., de Lope, L. R., Gonzalez-Rumayor, V., Romero, A., & Provencio, M. (2022). Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis. *Frontiers in Oncology*, 12, 943253.